Compare Southwest Airlines Co (LUV) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southwest Airlines Co vs Sanofi SA — how do they compare? Southwest Airlines Co trades at $41.41 (market cap $20.41B), while Sanofi SA trades at $40.1 (market cap $96.81B). The key difference: Sanofi SA is far larger — about 4.7× Southwest Airlines Co's market cap, and Sanofi SA pays the higher dividend (6.02%). Which is the better fit depends on your goals — on Pluang, investors hold Southwest Airlines Co for 65 Days and Sanofi SA for 94 Days on average.
| LUV | SNY | |
|---|---|---|
Market Cap | $20.41B | $96.81B |
Volume | 4,706,365 | 2,081,815 |
Sector | Industrials | Health |
52-Week High | $54.80 | $52.34 |
52-Week Low | $29.67 | $39.51 |
Typical Hold Time | 65 Days | 94 Days |
Enterprise Value | $23.51B | $116.20B |
Dividend Yield | 1.73% | 6.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southwest Airlines (LUV) trades at $41.72, down 1.72% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The company shows improving fundamentals with revenue growth from $28.06B in 2025 to projected $30.1B in 2026, though net margins remain thin at 2.78%. Recent earnings show volatility with a Q2 2026 beat but Q1 2026 miss, while analyst consensus leans slightly bullish with a $49.61 price target representing 19% upside potential.
LUV presents a transformation story with new revenue initiatives driving growth, but faces headwinds from high fuel costs and competitive pressures. The stock offers value with reasonable P/E of 26.08 and P/S of 0.73, though investors should monitor execution of commercial initiatives and fuel cost management. Near-term catalyst includes Q3 2026 earnings release on October 21, 2026.
SNY trades at $40.2, up 1.62% on the day, with a bearish technical signal from moving averages but a neutral oscillator stance. The company reported revenue of $46.72B in 2025 with a net income margin of 16.72%, and it has beaten EPS estimates for the last three quarters. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling strong pipeline development.
The outlook is mixed; analyst consensus leans hold (51.86%) with a buy rating at 44.44%, reflecting optimism on new drug launches but caution over future profit margin compression projected for 2026. Key risks include execution of the expanded Regeneron partnership and managing debt levels amid investing cash flow volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
